SCHEMBL1353024

SCHEMBL1353024

NC(=O)c1cccc2cccc(C(=O)O)c12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.64
NR4A1 P22736 1/20 0.50
NR4A2 P43354 1/20 0.50
NR4A3 Q92570 1/20 0.50
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
GAA P10253 1/20 0.48
PARP1 P09874 3/20 0.47
MAPT P10636 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
PDPK1 O15530 1/20 0.47
ALOX15 P16050 1/20 0.46
CYP1A2 P05177 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
PLK4 O00444 1/20 0.44
CHEK1 O14757 1/20 0.44
AURKA O14965 1/20 0.44
DAPK3 O43293 1/20 0.44
MAP4K4 O95819 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28163000 1.00 HSD17B10 (0.64) HSD17B10NR4A1NR4A2NR4A3KDM4E
SCHEMBL157601 0.91 KDM4E (0.55) HSD17B10KDM4EALDH1A1GAAPARP1
SCHEMBL14837758 0.89 KDM4E (0.53) HSD17B10KDM4EALDH1A1GAAPARP1
Benzene SCHEMBL28110156 0.89 HSD17B10 (0.78) HSD17B10NR4A1NR4A2NR4A3KDM4E
SCHEMBL68291 0.89 HSD17B10 (0.78) HSD17B10NR4A1NR4A2NR4A3KDM4E
SCHEMBL29404347 0.89 HSD17B10 (0.78) HSD17B10NR4A1NR4A2NR4A3KDM4E
SCHEMBL7624693 0.89 HSD17B10 (0.78) HSD17B10NR4A1NR4A2NR4A3KDM4E
Charcoal, Activated SCHEMBL5746941 0.87 HSD17B10 (0.75) HSD17B10NR4A1NR4A2NR4A3KDM4E
Hydrochloric Acid SCHEMBL10337055 0.87 HSD17B10 (0.75) HSD17B10NR4A1NR4A2NR4A3KDM4E
Lithium SCHEMBL7732118 0.87 HSD17B10 (0.75) HSD17B10NR4A1NR4A2NR4A3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110277948-A1 METHOD OF MONITORING AND INHIBITING SCALE DEPOSITION IN PULP MILL EVAPORATORS AND CONCENTRATORS NALCO COMPANY 2011-11-17 US claimed
EP-2142699-A1 METHOD OF MONITORING AND INHIBITING SCALE DEPOSITION IN PULP MILL EVAPORATORS AND CONCENTRATORS Nalco Company (US) 2010-01-13 EP claimed
WO-2008141121-A1 METHOD OF MONITORING AND INHIBITING SCALE DEPOSITION IN PULP MILL EVAPORATORS AND CONCENTRATORS NALCO COMPANY (US) 2008-11-20 WO claimed
US-20080277083-A1 METHOD OF MONITORING AND INHIBITING SCALE DEPOSITION IN PULP MILL EVAPORATORS AND CONCENTRATORS ECOLAB USA INC. 2008-11-13 US claimed
CN-117603148-A Pharmacokinetic enhancement of difunctional chelates and uses thereof 探针技术开发及商业化中心 2024-02-27 CN disclosed
CN-111263747-B Pharmacokinetic enhancement of difunctional chelates and uses thereof 探针技术开发及商业化中心 2023-10-27 CN disclosed
US-20220411582-A1 POLYALKYLENEIMINE-BASED POLYMERS CONTAINING POLYETHER CHAINS BASF SE (DE) 2022-12-29 US disclosed
US-20220403106-A1 POLYALKYLENEIMINE-BASED POLYMER CONTAINING POLYETHER CHAINS BASF SE (DE) 2022-12-22 US disclosed
US-8450726-B2 Articles containing coatings of amic acid salts EASTMAN KODAK COMPANY (US) 2013-05-28 US disclosed
US-8431433-B2 Methods of providing semiconductor layers from amic acid salts EASTMAN KODAK COMPANY (US) 2013-04-30 US disclosed
EP-2576501-A1 AROMATIC AMIC ACID SALTS AND COMPOSITIONS Eastman Kodak Company (US) 2013-04-10 EP disclosed
US-8404892-B2 Aromatic amic acid salts and compositions EASTMAN KODAK COMPANY (US) 2013-03-26 US disclosed
US-6395749-B1 Carboxamide compounds, methods, and compositions for inhibiting PARP activity GUILFORD PHARMACEUTICALS INC. 2002-05-28 US disclosed
WO-2002032856-A2 INSECTICIDAL 1,8-NAPHTHALENEDICARBOXAMIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2002-04-25 WO disclosed
US-20020019417-A1 Methods, compounds and compositions for treating gout EISAI INC. 2002-02-14 US disclosed
WO-2001091796-A2 METHODS, COMPOUNDS AND COMPOSITIONS FOR TREATING GOUT GUILFORD PHARMACEUTICALS INC. (US) 2001-12-06 WO disclosed
EP-1077944-A1 CARBOXAMIDE COMPOUNDS, COMPOSITIONS, AND METHODS FOR INHIBITING PARP ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 2001-02-28 EP disclosed
EP-1012153-A1 PARP INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS OF USING SAME GUILFORD PHARMACEUTICALS INC. (US) 2000-06-28 EP disclosed
WO-1999059973-A1 CARBOXAMIDE COMPOUNDS, COMPOSITIONS, AND METHODS FOR INHIBITING PARP ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 1999-11-25 WO disclosed
WO-1999011649-A2 PARP INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS OF USING SAME GUILFORD PHARMACEUTICALS INC. (US) 1999-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019417-A1 Methods, compounds and compositions for treating gout PARP2, PARP1, PARP3 HSD17B10 735/4885NR4A1 3900/4885NR4A2 4045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.